Arvest Bank Trust Division Has $22.28 Million Stake in Johnson & Johnson (JNJ)
Arvest Bank Trust Division increased its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 1.3% during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 168,420 shares of the company’s stock after acquiring an additional 2,101 shares during the period. Johnson & Johnson makes up about 1.7% of Arvest Bank Trust Division’s portfolio, making the stock its 13th largest holding. Arvest Bank Trust Division’s holdings in Johnson & Johnson were worth $22,281,000 at the end of the most recent quarter.
Several other large investors have also bought and sold shares of JNJ. Stokes & Hubbell Capital Management LLC increased its stake in shares of Johnson & Johnson by 5.3% in the 2nd quarter. Stokes & Hubbell Capital Management LLC now owns 97,608 shares of the company’s stock valued at $12,913,000 after purchasing an additional 4,924 shares in the last quarter. Pennsylvania Trust Co boosted its position in Johnson & Johnson by 21.2% during the second quarter. Pennsylvania Trust Co now owns 422,226 shares of the company’s stock worth $55,865,000 after purchasing an additional 73,975 shares in the last quarter. Hays Advisory LLC boosted its position in Johnson & Johnson by 5.4% during the second quarter. Hays Advisory LLC now owns 2,183 shares of the company’s stock worth $289,000 after purchasing an additional 112 shares in the last quarter. Gateway Investment Advisers LLC boosted its position in Johnson & Johnson by 2.1% during the second quarter. Gateway Investment Advisers LLC now owns 1,484,213 shares of the company’s stock worth $196,347,000 after purchasing an additional 30,640 shares in the last quarter. Finally, Bouchey Financial Group Ltd boosted its position in Johnson & Johnson by 3.8% during the second quarter. Bouchey Financial Group Ltd now owns 3,288 shares of the company’s stock worth $435,000 after purchasing an additional 121 shares in the last quarter. Hedge funds and other institutional investors own 65.90% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Arvest Bank Trust Division Has $22.28 Million Stake in Johnson & Johnson (JNJ)” was posted by Marea Informative and is the sole property of of Marea Informative. If you are viewing this news story on another domain, it was copied illegally and reposted in violation of US and international copyright legislation. The original version of this news story can be viewed at http://www.mareainformativa.com/arvest-bank-trust-division-has-22-28-million-stake-in-johnson-johnson-jnj/115755/.
In other news, VP Paulus Stoffels sold 102,692 shares of the company’s stock in a transaction on Monday, July 24th. The stock was sold at an average price of $133.14, for a total value of $13,672,412.88. Following the sale, the vice president now directly owns 230,342 shares in the company, valued at $30,667,733.88. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Dominic J. Caruso sold 82,591 shares of the company’s stock in a transaction on Thursday, July 20th. The shares were sold at an average price of $136.72, for a total value of $11,291,841.52. Following the completion of the sale, the vice president now owns 226,693 shares in the company, valued at $30,993,466.96. The disclosure for this sale can be found here. Company insiders own 0.19% of the company’s stock.
Johnson & Johnson (JNJ) traded up 0.56% during midday trading on Wednesday, reaching $132.84. 1,649,386 shares of the company traded hands. Johnson & Johnson has a 12 month low of $109.32 and a 12 month high of $137.08. The company’s 50-day moving average price is $132.27 and its 200 day moving average price is $129.78. The firm has a market capitalization of $356.54 billion, a PE ratio of 22.48 and a beta of 0.78.
Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Tuesday, July 18th. The company reported $1.83 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.79 by $0.04. Johnson & Johnson had a return on equity of 26.76% and a net margin of 22.52%. The firm had revenue of $18.84 billion during the quarter, compared to the consensus estimate of $18.94 billion. During the same period in the previous year, the firm posted $1.74 EPS. The company’s quarterly revenue was up 1.9% compared to the same quarter last year. On average, equities analysts anticipate that Johnson & Johnson will post $7.18 earnings per share for the current year.
The business also recently announced a quarterly dividend, which was paid on Tuesday, September 12th. Shareholders of record on Tuesday, August 29th were issued a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a yield of 2.54%. The ex-dividend date was Friday, August 25th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 56.76%.
Several analysts have commented on the company. Zacks Investment Research raised Johnson & Johnson from a “sell” rating to a “hold” rating in a report on Wednesday. Piper Jaffray Companies reaffirmed a “hold” rating and set a $120.00 target price on shares of Johnson & Johnson in a research note on Wednesday. UBS AG reiterated a “buy” rating and set a $148.00 target price on shares of Johnson & Johnson in a research report on Saturday. Citigroup Inc. assumed coverage on Johnson & Johnson in a research report on Monday, September 25th. They set a “neutral” rating and a $140.00 target price on the stock. Finally, Goldman Sachs Group, Inc. (The) cut shares of Johnson & Johnson from a “neutral” rating to a “sell” rating and lifted their price target for the company from $125.00 to $130.00 in a research note on Wednesday, September 20th. Five research analysts have rated the stock with a sell rating, ten have given a hold rating and eight have assigned a buy rating to the company. The company presently has an average rating of “Hold” and a consensus price target of $134.79.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Stock Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related stocks with our FREE daily email newsletter.